Fluid biomarkers of Lewy body diseases with cognitive disturbance

Abstract

Lewy body diseases (LBD) are defined as the accumulation of Lewy bodies composed of an aggregation of α–synuclein (αSyn). It was reported that not only the sole aggregation of αSyn but also the co–aggregation of amyloid–β (Aβ) and tau in LBD. Fluid biomarkers of pathogenic protein such as αSyn, Aβ and tau have been developed. We recently showed that plasma Aβ42/40 ratio was significantly decreased in patients with Aβ+LBD compared with those with Aβ–LBD.